Blog by: Kert Viele If you see a significant result in a manuscript, should you assume the result is biased? We often see discussions of
Join Dr. Cora Allen-Savietta of Berry Consultants presenting a platform trial in Parkinson’s disease on Oct 25.
Blog by: Joe Marion Forward: This post is about the continual reassessment method, a type of design used for phase I dose-finding studies, particularly in
Blog by: Kert Viele On Thursday, I will be moderating a panel session (PS3B, 9/28/2023, 4:15-5:30 p.m.) at the ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop
Berry Consultants is proud to sponsor next week’s ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop on September 27-29 hosted in Rockville, MD.
Blog by: Kert Viele Bayesians draw conclusions based on posterior probabilities and utilities. Once an experiment is complete, Bayesian draw the same conclusions with the
Live Zoom webinar sessions open to the public on “Introduction to Adaptive Trial Designs using FACTS” will be held this October and November.
Blog by: Kert Viele External or synthetic data aspires to shorten clinical trials, saving resources while maintaining scientific accuracy. Like any aspiration, external data may
New JAMA Guide to Statistics and Methods by Dr. Barbara Wendelberger and Dr. Roger Lewis explores the concept of futility in clinical trials.
Stop by our Berry Consultants booth to meet the team and get a demo of our latest software products (FACTS 7, ADDPLAN, & QUOTES).
© 2012-2024 All rights reserved - Berry Consultants